Global News

Valeant names Schiller Interim CEO

Thursday, January 7, 2016

Valeant Pharmaceuticals International has appointed Howard Schiller interim chief executive officer of Valeant, effective immediately. Schiller was Valeant’s chief financial officer from December 2011 through June 2015 and currently serves on Valeant’s board of directors. Valeant also announced that Robert Ingram, lead independent director, will serve as interim chairman of the board of directors.

[Read More]

Evotec, UCB ink management agreement

Thursday, January 7, 2016

Evotec has announced an EVT Execute collaboration aimed at providing a complete solution to UCB‘s global sample management requirements. Evotec will manage UCB’s compound collection out of its state-of-the-art sample management facility in Toulouse, France. The agreement covers an initial period of five years.

[Read More]

Quartet Medicine, Merck partner

Thursday, January 7, 2016

Quartet Medicine, a biotechnology company focused on the development of novel treatments for chronic pain and inflammation, has entered into a strategic agreement with Merck, known as MSD outside the U.S. and Canada, in connection with Quartet’s pipeline of novel small molecule drugs modulating the tetrahydrobiopterin (BH4) pathway.

[Read More]